
EXHIBIT 370



Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 4 of 117. PageID #: 167470 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 5 of 117. PageID #: 167471 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 6 of 117. PageID #: 167472 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 8 of 117. PageID #: 167474 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-	02804-DAP Highly Confi	Doc #: 1965-5 dential - Subj	2 Filed: 07/23/ect to Further	/19 16 of 117. F	PageID #: 167482 Review
REDACTE	D				

Highly Confidential - Subject to Further Confidentiality Review

REDACTED Page 60 1 But the simple question I asked you was: 2 Do you ever recall being educated on what 3 Walgreens' responsibilities as a distributor were? 4 Yes or no. 5 MR. SWANSON: Asked and answered. 6 BY THE WITNESS: 7 A. I relied on other people to make sure 8 that they knew that the -- Walgreens was following 9 the policies and procedures. 10 BY MR. MOUGEY: 11 Q. So, the answer to my question is no, 12 correct? You can't recall ever being educated on 13 what Walgreens' responsibilities as a distributor 14 were, correct? 15 MR. SWANSON: Object to form, mischaracterizes 16 her testimony. 17 BY THE WITNESS: 18 A. If that's how you want to interpret what 19 I'm saying. 20 BY MR. MOUGEY: 21 Q. You have said repeatedly that you relied 22 on other people, and I don't know if by relying on 23 other people that you just reviewed the reports and 24 someone else implemented. What I'm asking you is a Page 59 Page 61 1 from the beginning, just cut it off at 2015, you 1 simple question, and I'm going to ask it for about 2 don't believe that the work you performed was to 2 the fourth or fifth time. 3 ensure that Walgreens was filling its role as a 3 Do you recall ever being educated about 4 distributor, correct? 4 what Walgreens' responsibilities were as a 5 5 distributor? A. My role at various times, I was asked to б look at reports, look at item movement and б MR. SWANSON: Asked and answered. 7 determine if the logic was sound. How that was 7 BY MR. MOUGEY: 8 8 being interpreted in regards to various O. Yes or no. 9 regulations, I honestly didn't know how that fit 9 MR. SWANSON: Asked and answered. 10 in. 10 BY THE WITNESS: 11 Q. And you can't recall ever being educated 11 A. Again, I was relying on other people to

12 on what Walgreens' responsibilities as a 13 distributor were?

14 A. I'm sure I've heard different bits and

15 pieces of things over the courses of years, but

16 it's hard to pinpoint exactly when I would have

17 learned what types of information. And, again, my

18 role wasn't involved with determining what the

19 rules were. I was asked to determine if logic was 20 sound.

21 Q. My question was a little different. You 22

said, "I've heard bits and pieces over the years. 23 It's hard to pinpoint exactly when I learned

24 specific types of information." 13 BY MR. MOUGEY:

14 O. So, the answer is --

15 A. Our legal.

16 Q. -- no, you've never been educated --

determine what the regulations were.

17 MR. MOUGEY: I am sick and tired of the head 18 shaking on the yes and no from you two. I do not 19 want yeses, nos, in answers.

20 I will tell you what. We are going to

21 take a break. Do we have an extra camera? Do we 22 have another camera? Get the camera off of me and

23 let's put it on Walgreens counsel with the yeses

24 and nos and the head shaking repeatedly in the

12

Page 62 Page 64 peripheral sight of the witness. This has been MR. SWANSON: Asked and answered. 1 1 2 going on for two months with Kate over there 2 BY THE WITNESS: 3 3 shaking her head yes and no. A. Again, as far as regulations, I relied MR. SWANSON: You are not putting a camera on on our legal department to provide that guidance. 4 4 5 5 BY MR. MOUGEY: me. So, you can turn it off or keep it on you. 6 MR. MOUGEY: I do not want --6 Q. Did you -- did you -- were you trained 7 7 MR. SWANSON: Stop the speech. Ask questions. in any shape, form or fashion on Walgreens' 8 MR. MOUGEY: -- any more gestures. 8 responsibilities as a distributor? 9 There is no speech. I do not want any 9 A. Again, Walgreens' responsibilities, I more yes or no head shaking. It's the most 10 left that up to other people to determine. 10 11 11 Q. So, you didn't receive any training from unprofessional. And your office has done this 12 repeatedly over and over again for two months. 12 anyone else about what Walgreens' responsibilities 13 MR. SWANSON: Are you done? 13 and duties were as a distributor? 14 14 MR. SWANSON: Objection. MR. MOUGEY: Are you done? Are we done with 15 the head shaking? The witness is right there. 15 BY THE WITNESS: 16 MR. SWANSON: Do you need a breather? 16 A. It wasn't my area of responsibility to 17 MR. MOUGEY: The witness -- I don't need a 17 determine how to interpret rules and regulations. 18 breather. I need you to stop head shaking. 18 BY MR. MOUGEY: 19 MR. SWANSON: Then calm down. 19 Q. I understand that your -- you think it's 20 MR. MOUGEY: Don't tell me to calm down. 20 someone else. But all I'm simply asking is: Did 21 MR. SWANSON: And ask questions. 21 you get any training about what Walgreens' 22 22 MR. MOUGEY: I am sick and tired of Kate responsibilities were as a distributor? It's a 23 sitting there shaking her head in the direct 23 simple yes or no answer. 24 peripheral sight of the witness for answers. 24 And if it's no, it's okay. Just say no. Page 63 Page 65 1 THE WITNESS: I am not even looking at Kate. 1 If you didn't get any training about Walgreens' 2 MR. SWANSON: Nobody needs your speech, Peter. 2 responsibilities as a distributor, no is fine. 3 Go ahead. 3 A. I relied on other people to interpret 4 MR. MOUGEY: I don't need the head shaking. 4 the regulations. So, if you want to interpret that 5 Are you done with the head shaking? 5 as a no, please do so. б MR. SWANSON: I'm not going to respond. б Q. I'm not trying to interpret. I want you 7 MR. MOUGEY: Are you done with the head 7 to tell me generally do you ever recall being 8 8 trained on Walgreens' responsibility as a shaking? 9 MR. SWANSON: Do you want to go off the record 9 distributor? 10 and take a break or not? 10 A. And, again, my answer is it's not my 11 MR. MOUGEY: No, I don't need a break. 11 responsibility to interpret regulations. 12 MR. SWANSON: Then ask a question. 12 Q. So, I didn't use the word "regulations" 13 MR. MOUGEY: Are you done with the head 13 in my question. Okay. I have taken out "code." I've taken out "regulations." And I've used the 14 shaking? Yes or no. Are we done? 14 15 15 word "responsibilities." You understand the MR. SWANSON: Ask a question. 16 MR. MOUGEY: I will take that as a yes, we're 16 difference, correct? 17 done. And every time I get a head shake, I'm going 17 A. In this context, I'm not sure I do. Q. Okay. I'm not using the word 18 to announce it on the record. 18 19 "regulation." I'm not using the word "code." You MR. SWANSON: That's great. 19 20 MR. MOUGEY: That is great. 20 understand that, right? 21 BY MR. MOUGEY: 21 A. You didn't use those words, yes, I 22 Q. Do you recall ever being educated on 22 understand that. 23 Walgreens' responsibility as a distributor during 23 Q. And when I use the word "training," 24 24 at Walgreens, training was often done through your tenure at Walgreens?

Page 66 Page 68 PowerPoints or memos, things along those lines. 1 1 A. I was trusting --2 You understand that, right? 2 MR. SWANSON: Object to form. 3 3 A. More toward to the stores. I don't BY THE WITNESS: A. -- our legal department to interpret the 4 remember being trained as a corporate employee 4 5 5 using PowerPoint presentations. responsibilities. 6 Q. So, you went to conferences and attended 6 BY MR. MOUGEY: 7 7 conferences, correct? Q. I understand. That's not the question 8 A. I was reminded that I attended one 8 about who you were relying on. I asked did Barbara 9 conference. 9 Martin have an understanding of what Walgreens' 10 10 responsibilities were as a distributor? Did you Q. So, did you attend conferences or specifically, Barbara Martin, or were you relying 11 meetings or continuing education or anything 11 12 explaining what Walgreens' responsibilities were as 12 solely on other departments to fill that role? 13 a distributor? 13 A. I was relying on other departments to 14 14 A. I remember at some point. I don't fill that role, and as I've said over the course of 15 remember the date. It was brought up in 15 my years of experience, I've learned things. It's 16 discussions that I attended one seminar. It wasn't 16 hard to say what I learned when and when I learned 17 direct to Walgreens' roles and responsibilities. 17 it. So, if I learned something in '09, I can't 18 It was some company's presentation, and they were 18 recall if I learned it in '09, 2012 or two weeks 19 trying to sell their order patterns. 19 ago. 20 Q. That's the only time you remember any 20 Q. I didn't ask what year. I didn't ask 21 continuing education, seminar, explanation, about 21 what month. I didn't ask two weeks ago. What I've 22 22 what Walgreens' responsibilities as a distributor asked is: Does Barbara Martin have an 23 were, correct? 23 understanding of what Walgreens' responsibilities 24 That wasn't a continuing education 24 generally as a distributor are? Page 67 Page 69 1 1 seminar. I wish it would have been. I would have MR. SWANSON: Object to form, asked and 2 2 at least gotten some credit. answered. 3 Q. Right. But what I asked was: The only 3 BY THE WITNESS: 4 time you remember any educational piece about what 4 A. And I've relied on other people to 5 5 interpret what those responsibilities were. I Walgreens' duties or responsibilities were as a б distributor was a third-party conference that was 6 could -- once they would tell us what the 7 7 trying to sell a product? Yes? responsibilities were, I could then interpret that 8 8 A. Again, I wasn't there to interpret into my job as to how to look at reports or 9 Walgreens' regulations or responsibilities. I went 9 something like that if that was needed. 10 BY MR. MOUGEY: 10 more interested in to see what this company's logic 11 was doing and how to compare it to ours. 11 Q. And where did you -- who told you what 12 Q. And I appreciate that that you weren't 12 Walgreens' responsibilities were as a distributor? 13 there to interpret. I know you're not a lawyer. 13 A. We would have been relying on our legal 14 We have gone through your resume. I didn't ask if 14 department, Dwayne Piñon and his team, to review 15 you were there to interpret. 15 guidance. 16 16 What I've asked was: Other than the one MR. MOUGEY: Let's take a break. 17 seminar given by a third party, was there any 17 THE VIDEOGRAPHER: We are going off the record 18 18 instance generally where you were educated on at 10:15. 19 19 Walgreens' responsibilities as a distributor? (WHEREUPON, a recess was had 20 20 A. I relied on other people to interpret from 10:15 to 10:31 a.m.) 21 Walgreens' responsibilities. 21 THE VIDEOGRAPHER: We are back on the record 22 Q. So, you did not specifically have an 22 at 10:31. 23 understanding of what Walgreens' responsibilities 23 BY MR. MOUGEY: 24 24 were as a distributor, correct? Q. Ms. Martin, we are in '09, 2010 where

Page 70

Highly Confidential - Subject to Further Confidentiality Review

- 1 you are reviewing reports generated by Wayne
- 2 Bancroft's algorithm.
- 3 In a general description, can you tell
- 4 me what other areas of responsibility you had with
- 5 Walgreens suspicious order monitoring?
- 6 A. At that time all I was really doing was
- 7 looking at these reports in regards to order
- 8 monitoring. I had a lot of other roles and
- 9 responsibility in inventory.
- 10 Q. How many hours a week on average in '09
- 11 were you looking at these reports?
- 12 A. One to three maybe.
- 13 Q. And do you have an understanding of how
- 14 many hours a week in '09 Marcie was looking at
- 15 these reports?
- 16 A. I do not.
- 17 Q. How many reports would you look at
- 18 during the one to three hours a week?
- 19 A. It's difficult to quantify that. It
- 20 would depend on how easy they were to look at. The
- 21 one that we looked at, it's simple. 3 is smaller
- 22 than 5.
- 23 Q. Right.
- 24 There were others that I might have had
- Page 71 1
- to have done a much deeper dive into. So, no set 1 2 number. Depends on...
- 3
- Q. Are we talking a dozen, 15? Are we
- 4 talking 1,000?
- 5 A. Definitely not 1,000.
- б Q. Are we talking several hundred?
 - A. Again, it's -- it's hard to quantify.
- Could be anywhere between 10 to 75. I really don't 8
- 9 know.

7

- 10 Q. How about less than 100, more than 10 a
- week? Is that fair? Somewhere in that range? 11
- 12 A. That sounds fine.
- 13 Q. Did you and Marcie Ranick divide them up
- 14 in any way that she looked at some and you looked
- 15 at others?
- 16 A. No. When she came down, we would spend
- 17 time together going through things, and then I'm
- 18 sure she was looking at stuff on her own. But I
- 19 don't know what she was doing.
- 20 Q. How would you determine, I'm going to
- 21 call it a batch that you would look at, the 10 to
- 22 less than 100 you'd look at a week?
- 23 Randomly pulling up reports.
- 24 Do you have an understanding of how many

- 1 reports were being flagged on a weekly basis in
- 2 2009?

3

5

11

- A. I don't remember.
- 4 O. Thousands?
 - I wouldn't even want to take a guess.
- 6 Sorry.
- 7 Q. Is there anywhere at Walgreens where the
- 8 orders that were being flagged by Wayne Bancroft's
- 9 algorithm were kept?
- 10 A. I don't believe that data is stored
 - anywhere.
- Q. So, a report would populate and it would 12
- 13 just disappear into the Internet?
- 14 A. The reports populated. They held for a
- 15 period of time. I don't remember what that period
- 16 of time is or was. I know that our algorithms and
- 17 order of monitors and order of logic have been
- 18 evolved over the years; and with that, there would
- have been different types of reporting that would 19
- 20 have replaced the stuff I was looking at.
- 21 Q. There were a batch of I'm going to say
- 22 20, 25 different individual pieces of paper printed
- 23 like the document I put in front of you as
- 24 Martin -- I believe it was 2.

Page 73

Page 72

- Do you have an understanding of -- did
- 2 you have a paper file of 20 or 25 of those reports 3
 - from Bancroft's algorithm?
 - A. I don't remember. I mean, I know I kept
- 5 a sample of the reports. How many they were, I
- 6 don't remember.
- 7 Q. Why did you keep a sample of the 8
 - reports?

4

- 9 A. I guess I just kept them just to see how
- 10 our system evolved over the years. I'm not really
- 11 sure why.
- 12 Q. Did you look at them in preparation for 13 today?
- 14 There were a few that we looked at, yes.
- 15 Q. All right. So, we've gone through your
- 16 participation in Walgreens' suspicious order
- 17 monitoring policies up until 2009 I believe. Okay?
- 18 Can you give me any more examples moving
- 19 forward in time of your different roles?
- 20 A. In relationship to the order monitoring
- 21 process or my roles in general with inventory?
- 22 Q. Walgreens -- as far as your role is what
- we're talking about, your role with reviewing 24 procedures and policies, reports for Walgreens

23

Highly Confidential - Subject to Further Confidentiality Review

2

implementing its responsibilities as a distributor. 1

A. I wasn't responsible for writing SOPs

- 3 for Walgreens. I know that I provided information
- for guidance for the stores and how to look up 4
- 5 things, but I wasn't writing SOPs.

2

8

9

- 6 Q. Okay. And I'm -- I'm sorry. I don't
- 7 think I used the word "writing SOPs." So, just
 - we're getting -- going through --
 - A. Sorry. I misinterpreted what you said.
- 10 Q. General understanding. Seems to be a
- 11 little bit of a problem for the last two hours.
- 12 So, generally your roles with Walgreens
- 13 and its suspicious order monitoring policies, what
- 14 are some of the roles you filled? That's what I'm
- 15 asking you to describe to me.
- 16 So, you didn't write the policies. We
- 17 got that. You're not a lawyer. We got that.
- 18 You're not interpreting anything. I got that. You
- 19 can't remember any specific education or training
- 20 with Walgreens as a distributor.
- 21 Just give me some general descriptions
- 22 of other duties you filled with Walgreens'
- 23 suspicious order monitoring policies.
- 24 MR. SWANSON: Object to the lawyer testifying,

but you can answer the question if you understand

- Page 74 Page 76 A. So, I would have been continuing to work 1
 - with Marcie to help her review and understand these
 - 3 reports. I would also work with her when she came
 - 4 down to look at the monthly and quarterly reports.
 - 5 Again, we had talked previously about me
 - 6 supplying data when it was requested regarding
 - 7 purchases.
 - 8 Q. So, you continued to work with Marcie
 - 9 and help her review and understand the reports.
 - 10 That's one topic, right?
 - 11 A. Um-hmm.
 - 12 Q. You also worked with her when she came
 - 13 down to look at the monthly and quarterly reports,
 - 14 correct?

17

19

20

- 15 A. Right.
- 16 Q. Kind of the same area, right?
 - And then supplying data or data when
- 18 asked, right?
 - A. Um-hmm.
 - Q. Is there any other roles Barbara Martin
- 21 filled until the end of 2015 in relation to
- 22 Walgreens' suspicious order monitoring policies and
- 23 procedures?
- 24 A. It's hard to think of something right

1 off the top of my head. I'm sure I had

- 2 correspondence and communication with other team
- 3 members.

4

- Q. So, when we look at your resume,
- 5 Martin 1, the only entry I see on your entire
- 6 resume in relation to Walgreens' suspicious order
- 7 monitoring policies and procedures with regard to
- 8 its role as a distributor is that last entry,
- 9 "assisted in the creation of the control drug order
- monitoring reports." Do you see anything else? 10
- 11 That's -- that's the one that talks
- 12 about order monitoring, yeah.
- 13 Right. Q.
- 14 For potentially suspicious orders.
- 15 Q. Anything else on your resume where
- 16
- you're describing your, Barbara Martin's, roles or 17
- duties in relation to Walgreens' suspicious order
- 18 monitoring policies and procedures as a
- 19 distributor?
- 20 A. I -- I can't think of anything.
- 21 Q. All right. So, let me just make sure if
 - I can get a general understanding of what you were
- 23 doing.

22

24

You helped create the drug order

Page 75

it.

2

1

- 3 BY THE WITNESS:
- 4 A. What time frame are you talking about?
- 5 BY MR. MOUGEY:
- б Q. We are moving on from 2009. So, I think
- 7 we've captured everything up to 2009, correct?
- 8 A. To the best of my recollection.
- 9 Q. To the best of your recollection. So,
- 10 let's -- moving forward, give me some general
- 11 descriptions of your duties with Walgreens'
- 12 suspicious order monitoring policies and
- 13 procedures.
- 14 A. Again, what time -- we're looking at
- 15 2010 now?
- 16 Q. I'm just -- you don't remember dates 17 specifically.
- 18 A. No, that's what I'm trying to --19
- Q. I understand. I'm saying moving through 20 '09 and afterwards. I'm giving you a really broad
- 21 window for you to generally describe to me what
- 22 Barbara Martin did in relation to Walgreens'
- 23 suspicious order monitoring policies and
- 24 procedures.

Page 77

Page 78

Highly Confidential - Subject to Further Confidentiality Review

2

3

8

- monitoring reports, correct? By "create," you 1
- 2 provided some input into the reports. Is that --
- 3 is that fair?

4

7

8

- A. Yeah, I mean, I didn't design the
- 5 report, but I looked at the data that was generated
- б off of the reports.
 - Q. And you gave input on some of the data
 - that the reports were flagging. Is that fair?
- 9 A. Yes.
- 10 Q. All right. You pulled data kind of on
- 11 an ad hoc basis when people would ask. Is that
- 12 fair?
- 13 A. Yes.
- 14 Q. All right. And you helped Nancy --
- no -- Marcie Ranick interpret some of these reports 15
- 16 and understand the flow within the inventory. Is
- 17 that fair?
- 18 A. Yes.
- 19 Q. All right. Am I kind of capturing your
- 20 recollection of what Barbara Martin did in relation
- 21 to Walgreens as a distributor in relation to its
- 22 suspicious order monitoring policies and
- 23 procedures?

1 2

3

4

5

б

7

8

9

24 Yeah, I mean, there might have been

other things. Nothing comes to mind. And, again,

Q. Now, let me maybe make sure you and I

So, if I were to change the question and

aren't talking past each other and the use of the

word "distributor" maybe is causing you some

say describe to me your roles, Barbara Martin's

- corporate level, correct? 1
 - A. Um-hmm.
 - Q. So, post-2004, would you describe to me

Page 80

Page 81

- 4 what, if any, roles you had assisting Walgreens
- 5 with its compliance in its role as a distributor?
- 6 I'm sorry. As a pharmacy.
- 7 A. I'm sorry. I'm struggling with how to
 - answer that question, because when I think of like
- 9 Walgreens as a pharmacy, I would think of each
- 10 individual pharmacy.
- 11 Q. Fair enough. And if your answer is no,
- 12 I really didn't have jobs or duties in relation to
- 13 ensuring Walgreens was compliant in its role as a
- 14 pharmacy, that was more at the pharmacy level, then
- 15 that's a fine answer.
- 16 I'm just trying to understand what
- 17 Barbara Martin did and didn't do. So, if that was
- 18 something that you didn't do, that's okay. I just
- 19 want to know so I can figure out what to do with
- 20 the rest of our time.
- 21 Did Barbara Martin have any jobs or
- 22 responsibilities or duties post-2004 where you were
- 23 helping Walgreens with its compliance, good faith
- 24 dispensing, as a pharmacy?

Page 79

1

13

2 I was more store-facing than distribution.

- 4 for interpreting the regulations. But what I did
- 5
- 6 these reports and other data. You know, I'm sure I
- 8
- roles, at Walgreens in relation to Walgreens 10 filling its role as a pharmacy through, for

questions about your answer.

- example, good faith dispensing. Did you have 11
- 12 any -- did you have any duties in that respect?
- 13 A. I was aware of good faith dispensing.
- 14 It was something that I was taught back in pharmacy
- 15 school. I practiced it when I was a pharmacist in
- 16 the stores. I wasn't involved with writing the
- 17 Walgreens procedures for good faith dispensing, but
- 18 generally aware of them through my entire career
- 19 starting in school.
- 20 Q. So, you were a pharmacist, both a
- 21 staff -- an intern, a staff pharmacist and a
- 22 pharmacy manager all the way up to 2004, correct?
- 23 Yes. A.
- 24 So, post-2004, when you were more at the

- MR. SWANSON: Object to form.
- BY THE WITNESS:
- 3 A. So, I mean, I wasn't really responsible
- focus on, again, we can go back to I was looking at
- 7 had conversations with various groups. It's hard
- to remember what I've done in the last 30 years.
- 9 But, again, these reports were a big job
- 10 and then as we got out of these reports and the
- 11 system got more sophisticated, I transitioned back
- 12 into other inventory supporting roles.
 - BY MR. MOUGEY:
- 14 Q. But I think what you told me earlier
- 15 this morning is that you were pulling the data
- 16 pulls and you weren't reviewing those. You were
- 17 simply giving the data you were asked to pull to
- the field. Correct? 18
- 19 A. Correct.
- 20 Q. So, let's partition that one aside.
- 21 Okay?
- 22 So, the only reports that you were
- 23 looking at were the ones that you and Marcie were
- 24 looking at during the pilot phase. Is that fair?

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 24 of 117. PageID #: 167490 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-	O2804-DAP Highly Confi	Doc #: 1965-	52 Filed: 07/23 ject to Further	3/19 29 of 117. Confidentiality	PageID #: 167495 Review
REDACTE	ED				

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 32 of 117. PageID #: 167498 Highly Confidential - Subject to Further Confidentiality Review
REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 33 of 117. PageID #: 167499 Highly Confidential - Subject to Further Confidentiality Review
REDACTED

	Highly	Confidential	- Subject	to Further	Confidentiality	Review
REDACT	ED					
KLDIICI						

Case: 1:17-md-02804-DAP_Doc #: 1965-52_Filed: 07/23/19_34 of 117. PageID #: 167500

Case: 1:17-md-	- <mark>02804</mark> -	DAP Confi	Doc #: dential	1965-52 - Subject	Filed:	07/23/ 1rther C	19 40 of onfident	117. Fiality	PageID #	: 167506
REDACT	ED									

Case: 1:17-md	- <mark>02804</mark> - Highly	DAP D	OC #: 1	. <mark>965-52</mark> - Subjec	Filed: (07/23/19	9 42 of 11 nfidential	7. PageID #	#: 16750 8
REDACT									

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 44 of 117. PageID #: 167510 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-	O2804-DAP Highly Confid	Doc #: 1965-52 dential - Subje	2 Filed: 07/23/19 ct to Further Co.	9 45 of 117. Pag	geID #: 167511 riew
REDACTI	ED				

Case: 1:17-md-0280	04-DAP Doc#: ly Confidential	1965-52 Filed: - Subject to Fu	07/23/19 46 of 1 arther Confidentia	17. PageID #: 16	7512
REDACTED					

Case: 1:17-md-02804-DAP	Doc #: 3	1965-52	Filed:	07/23/19	48 of 117.	PageID #: 167514
REDACTED						

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 50 of 117. PageID #: 167516 Highly Confidential - Subject to Further Confidentiality Review

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 53 of 117. PageID #: 167519 Highly Confidential - Subject to Further Confidentiality Review

Case: 1:17-m	d-02804-DAP Highly Confi	Doc #: 1965-5	2 Filed: 07/23/3	19 54 of 117. Page 19 19 19 19 19 19 19 19 19 19 19 19 19	ageID #: 167520
REDACT	ED				

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 56 of 117. PageID #: 167522 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 57 of 117. PageID #: 167523 Highly Confidential - Subject to Further Confidentiality Review

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 58 of 117. PageID #: 167524 Highly Confidential - Subject to Further Confidentiality Review

Case: 1:17-md-0	2804-DAP C	Ooc #: 1965-52 ential - Subject	Filed: 07/23/1 ct to Further C	L9 59 of 117. Ponfidentiality F	ageID #: 167525 Review
REDACTE	D				

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 61 of 117. PageID #: 167527 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Golkow Litigation Services - 877.370.DEPS

61 (Pages 238 to 241)

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 63 of 117. PageID #: 167529 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Highly	Confidential - Sub	oject to Further C	onfidentiality Revi	ew
REDACTED				

Case: 1:17-md-02804-DAP_Doc #: 1965-52_Filed: 07/23/19_64 of 117. PageID #: 167530

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 65 of 117. PageID #: 167531 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 66 of 117. PageID #: 167532 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 67 of 117. PageID #: 167533 Highly Confidential - Subject to Further Confidentiality Review

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 68 of 117. PageID #: 167534 Highly Confidential - Subject to Further Confidentiality Review REDACTED

69 (Pages 270 to 273)

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 71 of 117. PageID #: 167537 Highly Confidential - Subject to Further Confidentiality Review REDACTED

REDACTED REDACTED 17 BY MR. MOUGEY: 18 Q. I understand, and I'm not asking you to 19 identify the specific person or the specific time. 20 But you can't remember one instance from 21 June of '08 into now April of 2012 where somebody 22 says, "We need to correct all of these memos. 23 They're wrong. We need to put the word 'possible' 24 or 'potential' in front of 'suspicious," correct? Page 283 1 A. I have no memory of that, correct. 2 Q. Now, if you turn to Bates No. 44 3 under 9. 4 "Start saving 52 weeks of order history 5 data for more accurate observations. The process 6 was already changed in December 2010 to purge the 7 order history after 52 weeks." 8 Did I read that right?

order history data was needed for more accurateobservations?

A. Well, that's the reason, to get more

A. Yes, you read that correctly.

Q. Okay. I have two questions. Do you

owner of this specific memorandum, why 52 weeks of

understand what the reason is, as the business

16 accurate observations.

REDACTED


9

10 11

12

	Page 286	Page 288
REDACTED		
REDACTED		

75 (Pages 294 to 297)



Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 78 of Highly Confidential - Subject to Further Confident REDACTED	117. PageID #: 167544 iality Review
REDACTED	

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 79 of 117. PageID #: 167545
Highly Confidential - Subject to Further Confidentiality Review REDACTED

Golkow Litigation Services - 877.370.DEPS

HIGHI	y Confidential - S	ubject to further	Confidentiality Re	sview
REDACTED				
REDITCTED				

Case: 1:17-md-02804-DAP_Doc #: 1965-52_Filed: 07/23/19_81 of 117. PageID #: 167547

Page 318

Highly Confidential - Subject to Further Confidentiality Review

1 regulatory and law, Patty Zagami, correct?

- A. Her name is listed here too, yes.
- Q. Yes, ma'am. And now if you look above
- 4 that, Anika Madarasz. Can you help me out with
- 5 that?

2

- 6 A. I vaguely remember her.
- 7 Q. Okay.
- 8 A. I'm not comfortable correcting your
- 9 pronunciation.
- Q. All right. And then -- so, that e-mail
- then is forwarded to several people, correct?
- 12 A. Yes, she sent this e-mail to a number of
- 13 different people, yes.
- 14 Q. And then Mike Bleser sent the e-mail to
- 15 you, correct?
- 16 A. Me, Denny and Frank.
- Q. I might just be tired. But do you see
- 18 Anika, Anika's name anywhere on that e-mail below?
- 19 A. I do not.
- Q. Do you have any understanding of how
- 21 Anika could forward an e-mail that we don't see her
- 22 copied on?
- A. Someone cut something out. I -- I don't
- 24 know.

1

- Q. And then Mr. Bleser forwarded the
- 2 contents of the e-mail to you, correct?
- 3 A. Correct.
- 4 O. So, let's look back down at Mr. Swords'
- 5 e-mail to Kermit Crawford, amongst others, and what
- 6 I want to direct your attention to is that he's
- 7 referencing a November 8th DEA meeting at NAPB,
- 8 correct?
- 9 A. That's the subject line, yes.
- 10 Q. I forget the acronym. National
- 11 Association of?
- 12 A. Boards of Pharmacy.
- Q. There you go.
- And he relays that "I have the sense
- 15 that today's meeting was a condensed version of the
- 16 regional meetings the DEA is holding throughout the
- 17 country for pharmacists." He references that he
- 18 thought several of the chains were there.
- Do you see that?
- 20 A. Yes.
- Q. But below that, what I want to point
- 22 out, do you see Joseph Rannazzisi?
- A. I see his name, yes.
- Q. Yes, ma'am. And do you recognize his

1 name as the gentleman that signed the three letters

Page 320

- 2 that we went through earlier from the DEA in 2006,
- 3 early 2007 and late 2007?
- 4 A. I don't remember looking at the
- 5 signatures of those letters.
- 6 Q. And if you'd turn the page to Bates
- 7 No. 47, at the top of the page, the fourth bullet
- 8 down, "Reviewed 21 CFR 1301.74." Are you there
- 9 with me?

11

21

23

1

7

13

16

22

- 10 A. Yes, I see that.
 - Q. And you recognize that language. That
- was in all of the letters that we reviewed from the
- DEA in 2006 and 2007 about the registrant designing
- and operating "a system to disclose to the
- 15 registrant suspicious orders of controlled
- 16 substances." Correct?
- 17 A. That's what this says, yes.
- Q. And the bullet below, "If suspicious -
- 19 you don't ship. Decreasing the order and shipping
- 20 is not complying with the regulation."
 - Did I read that right?
- A. You read that correctly, yes.
 - Q. So, we just looked at a Buzzeo
- 24 presentation that you attended in October of 2012

Page 321

- and within a month of the Buzzeo presentation
- 2 Mr. Rex Swords is at another meeting with the DEA
- 3 where he's being told, "Decreasing the order and
- 4 shipping is not complying with the regulation,"
- 5 correct?
- 6 A. That's what this says, yes.
 - Q. And this was sent to you as well,
- 8 correct?
- 9 A. It was forwarded on to me, yes.
- Q. And then the next bullet says, "Ignoring
- 11 suspicious orders will result in civil penalties.
- 12 Cited Cardinal, ABC and McKesson fines."
 - Correct?
- 14 A. That's what that statement says, yes.
- Q. Now, let's go down to three-quarters of
 - the page and you see "Red Flags"?
- 17 A. Yes, I see that.
- Q. And at least some of these red flags are
- 19 the same red flags that were identified in the
- 20 Buzzeo presentation, correct?
- 21 A. I believe so.
 - Q. And this is coming directly from the DEA
- 23 to Walgreens, correct?
- 24 MR. SWANSON: Object to form, lacks

Page 322 Page 324 1 foundation. 1 others. Do you see that? 2 BY THE WITNESS: 2 A. I don't have a copy of the paper yet. 3 3 Q. I'm sorry, Ms. Martin. A. It's coming from an e-mail that Rex 4 wrote 4 (WHEREUPON, a certain document was 5 BY MR. MOUGEY: 5 marked as Walgreens-Martin Exhibit 6 Q. Yes, ma'am. Where he references a 6 No. 29: 8/3/10 e-mail with 7 7 meeting with Joseph Rannazzisi, the Deputy attachments; WAGMDL00660331 -8 Administrator -- Deputy Assistant Administrator, 8 00660337.) 9 Office of Diversion Control, correct? First page, 9 BY MR. MOUGEY: 10 middle of the page. 10 Q. Do you have it in front of you, 11 A. Yes. Ms. Martin? 11 12 Q. And he -- Mr. Swords goes on, 12 A. Yes, I do. 13 "Mr. Rannazzisi presented a large PowerPoint deck 13 Q. All right. This is an e-mail from 14 on prescription drug trafficking and abuse for two 14 Daniel Coughlin to yourself, amongst others, dated hours," correct? "Approximately two hours," August 3, 2010, correct? 15 15 16 correct? 16 A. It's to Marcie, and I'm cc'd among 17 17 another bunch of people. A. That's what that says, yes. 18 Q. So, you, your boss, Mr. Bleser, 18 Q. Yes, ma'am. And including Mr. Piñon, 19 Mr. Murray and several senior members of Walgreens 19 correct? 20 management were put on alert that decreasing the 20 A. Yes, I see his name. 21 order and shipping is not complying with the 21 Q. Do you recall who Daniel Coughlin is? 22 22 regulation as of November 9, 2012, correct? A. I know he had something to do with the 23 A. That's what this document says, yes. 23 distribution centers. I'm not sure of his exact 24 Did Walgreens take the information that 24 title. I want to say vice president. Page 325 Mr. Swords passed around and change its algorithm 1 Q. Do you know if he was in a specific 1 2 2 to no longer cut what it internally was calling a distribution center or was he in corporate? 3 suspicious order? 3 A. I don't remember where he was based. 4 MR. SWANSON: Object to form, lacks 4 Q. So, the subject line is "Suspicious foundation. 5 5 Controlled Drug Orders." б BY THE WITNESS: 6 Do you see that? 7 A. I know over the years we have made a lot 7 A. Yes, I see that subject line. of different changes. What we did when is a little 8 8 Q. And he had two questions. Do you see 9 bit vague to me. But I would believe that, yes, we 9 that it's No. 1 and No. 2? 10 did act on this information. 10 A. Yes, I see that. 11 BY MR. MOUGEY: 11 Q. And No. 1, he said, "I recall the old 12 Q. Do you recall that version 5.5, which 12 paper report as being inches thick. This was 13 was entered after these October and 13 replaced by same data on disk and eventually electronic transmission. We were instructed in 14 November e-mails, still included in the algorithm a 14 15 15 1985 not to review or contact anyone on the data." suspicious order being cut and not reported to the 16 DEA? 16 Did I get that right? 17 MR. SWANSON: Object to form. 17 A. That's what this says, yes. 18 BY THE WITNESS: Q. Okay. "Who from your group has been 18 19 A. I don't remember that directly off the 19 reviewing the data collected for the past 25 20 top of my head. 20 vears?" 21 BY MR. MOUGEY: 21 Now, did that give you some pause for 22 Q. Ms. Martin, I want to go back in time to 22 alarm in August 3 of 2010 that Mr. Coughlin was 23 August of 2010. Mark this as Martin 29. This is 23 asking Ms. Ranick in Loss Prevention and copying 24 an e-mail from Daniel Coughlin to yourself, amongst 24 you asking who has been reviewing the suspicious

Page 326 Page 328 controlled drug orders for the last 25 years? A. No, it was not me. We didn't have --1 1 2 MR. SWANSON: Object to form, foundation. 2 the program that I worked on didn't exist 25 years 3 3 BY THE WITNESS: ago. 4 A. This e-mail wasn't sent to me. So, I 4 BY MR. MOUGEY: 5 don't know what Marcie or her team was doing and --5 Q. At any point in time in your tenure at 6 BY MR. MOUGEY: 6 Walgreens that we have been discussing today from 7 7 Q. Did you ask? the suspicious order monitoring that you were 8 A. I personally did not. 8 involved in, so, from 2008 to 2012, were you 9 Q. And did you not ask because when you 9 charged with reviewing suspicious controlled drug look at an e-mail like this that you've got Dwayne 10 10 orders to perform due diligence to ensure the 11 Piñon from legal on this that you assumed that 11 viability of those orders going to legitimate regulatory and law was ensuring that Walgreens was 12 12 patients outside of just testing the validity of 13 complying with its obligations as a distributor 13 the reports? 14 under the federal code and the federal regs? 14 MR. SWANSON: Object to form. 15 15 MR. SWANSON: Object to form. BY THE WITNESS: 16 BY THE WITNESS: 16 A. Yes, I was performing due diligence on 17 A. I was assuming that if this was 17 some of those reports. 18 addressed to Marcie, that her and her team were 18 BY MR. MOUGEY: 19 Q. And define for me what you mean by due taking appropriate action. 19 20 BY MR. MOUGEY: 20 diligence. 21 Q. 25 years. Who has been reviewing these 21 A. I would look at data. I would look at 22 22 reports for the last 25 years, somebody from the the store's history and see if it made sense. If 23 distribution center, under suspicious drug 23 something didn't make sense to me, I would call the 24 controlled drug orders. That doesn't make you stop 24 store or the district manager or the pharmacy Page 327 Page 329 1 what you're doing for the course of the day and 1 supervisor and try to obtain additional 2 2 follow up? 25 years? information. 3 A. It wasn't my area of responsibility. 3 Q. And that was part of your 4 Q. Did it not give you any concern that a 4 responsibilities in the, you know, a few hours up 5 to ten hours a week reviewing the reports from the 5 member of Walgreens distribution center is asking б who has been reviewing our suspicious controlled 6 algorithm? 7 drug orders for the last 25 years? 7 A. Yes. 8 MR. SWANSON: Object to form. 8 Q. Let me hand you Martin 30. 9 BY THE WITNESS: 9 (WHEREUPON, a certain document was 10 A. He's asking a question. We don't know 10 marked as Walgreens-Martin Exhibit 11 based on this e-mail who was or who wasn't doing 11 No. 30: 1/10/11 e-mail string; 12 it. Just because he's asking who doesn't mean it 12 WAGFLDEA00000846 - 00000851.) 13 wasn't being done. 13 BY MR. MOUGEY: 14 BY MR. MOUGEY: 14 Q. This is an e-mail chain with you 15 15 included and Kristine Atwell. Are you familiar Q. And it certainly wasn't you, correct? 16 A. This reporting was not my area of 16 with Ms. Atwell? 17 responsibility. 17 A. I remember her name, yes. Q. Yes, ma'am. You remember her name from 18 Q. And not just reporting. Reviewing. 18 19 What he is asking is who from the group has been 19 this e-mail exchange? 20 reviewing the data collected for the last 25 years, 20 A. Yeah. I remember we had -- she worked in 21 suspicious controlled drug orders. That was not Jupiter. We had a number of different 21 22 you, correct? 22 conversations via either phone call or e-mails. 23 23 MR. SWANSON: Object to form. Q. She worked at the Jupiter distribution 24 BY THE WITNESS: 24 center?

Page 330 Page 332 1 Yes. 1 you're purchasing or returning C-II drugs. A. 2 2 Q. The one that was padlocked by the DEA, Q. "This is creating an issue in 3 3 correct? maintaining enough 222 forms to fill all of the 4 MR. SWANSON: Object to form. 4 orders because a new 222 form is generated for 5 BY MR. MOUGEY: 5 every 128 bottles of this WIC," and that is the --6 Q. Correct? 6 what's WIC stand for again? 7 7 A. She worked in Jupiter, yes. A. Walgreens item code. 8 Q. Yes, ma'am. The same Jupiter that the 8 Q. -- "that are ordered. For example, when 9 DEA came in and locked up the cage and kept 9 they order 450 bottles, there will be four 222 Walgreens from accessing its Schedule II and forms printed to accommodate this one order. I 10 10 11 Schedule III opiates, correct? feel that this store needs to justify the large 11 12 A. That's in a different time period than 12 quantity." 13 this e-mail. 13 Did I read that right? 14 14 Q. Yes, ma'am. That's not what I asked. A. That's what she wrote, yes. 15 What I simply asked you was: This is 15 "Three stores that come to mind are," 16 the same Jupiter that was ultimately where the 16 and I'm going to -- I want you to help me remember 17 locks were changed by the DEA, correct? these. Write these down. Do you have a pen over 17 18 there? A. Yes. 18 19 Q. And this e-mail chain is dated 19 A. I do not. 20 January 10, 2011, correct? 20 Okay. 7298, 3836 and 5018. Okay. Got 21 A. That is correct. Yes. 21 it? 22 22 O. And if we start at the bottom of this A. I might have to flip back and forth. 23 e-mail chain on Bates No. 51, the very last page, 23 Q. All right. We'll just kind of put this 24 there is two sets of Bates numbers. This is 24 document off to the side. Page 331 Page 333 1 WAGFLDEA851, very last page. 1 So, essentially Ms. Atwell is asking 2 2 A. Yes, I see that. you, these stores should justify these large 3 O. You can see this is an e-mail from 3 amounts of Schedule II controlled substance. 4 Kristine Atwell. 4 correct? 5 5 "What are your thoughts on this matter?" A. Of this particular item, yes. б Do you see that? 6 Q. Yes, ma'am. And you respond to her on 7 A. I see that, yes. 7 Bates No. 49 and reply, "I am able to look at store 8 8 item movement if this helps." Q. Okay. Let's go to the previous 9 page where Ms. Atwell from the Jupiter distribution 9 Do you see where I am? 10 center asks you, "I have" -- and I'm on Bates 10 A. Yes. "You can contact the store for more 11 No. 50 -- "I have several stores that are ordering 11 12 huge quantities of 682971 on a regular basis." 12 information." 13 And that is a controlled substance, 13 So, you didn't contact the store. You 14 correct? 14 told her to contact the store. Correct? 15 A. Off the top of my head I don't remember 15 A. That's what I wrote, yes. 16 what that WIC number is associated with, but --16 Q. Somebody in the distribution center, 17 Q. This is -- I'm sorry. Go ahead. Were 17 correct? 18 you finished? 18 A. That's what I wrote, yes. 19 A. We'll just assume it's some kind of a 19 Not Barb Martin performing the due 20 C-II because she is mentioning the 222 forms. 20 diligence. You told her to contact the store, 21 Q. Yes, ma'am. The 222 forms need to be 21 correct? 22 filled out when a certain amount of controlled 22 MR. SWANSON: Object to form. 23 23 BY THE WITNESS: substances are shipped, correct? 24 A. The 222 form is required by the DEA when 24 A. I told Kristine to reach out to the

Page 334 Page 336 1 1 redo that. store, yes. 2 BY MR. MOUGEY: 2 Ms. Atwell responds to you. That makes 3 3 Q. You said, "These sales are quite high it even better. 4 compared to other non-Florida stores." 4 She runs "a query to see how many 5 Correct? 5 bottles we have sent," and she says, "store 3836," 6 A. That's what I wrote, yes. 6 "and we have shipped them 3271 bottles between 7 7 12/1/10 and 1/10/11." Q. "Store 7298 sells about 22,000 tabs of 8 682971 every week." 8 Now do I have that right? That's from 9 Correct? 9 her to you, correct? 10 10 MR. SWANSON: Object to the preface. Go ahead A. That's what I wrote, yes. 11 "That translates to 220 bottles per 11 and answer. 12 week." 12 BY MR. MOUGEY: 13 Is that "SO"? Is that supposed to be 13 Q. That's from her to you, correct? "of"? 14 14 A. Yes, she wrote this e-mail. 15 Oh, I'm sorry. Never mind. 15 Q. So, she runs the query and then she 16 "That translates to 220 dollars per 16 says, "I don't know how they can even house this 17 week, so 450 bottles is more than a two-week 17 many bottles to be honest." 18 supply." (As read.) 18 Correct? Did I get that right? 19 Did I get that right? 19 A. That's what she wrote, yes. 20 A. I wrote "a little more than a two-week 20 "How do we go about checking the 21 supply." 21 validity of these orders?" 22 22 Q. Yes, ma'am. And if you turn to Bates Correct? 23 No. 47, you e-mailed her again and said, "I ran a 23 A. That's what she wrote, yes. 24 query to see how many bottles we have sent to store 24 Here we are, Barb Martin doing due Page 337 diligence on the store, gets contacted by the 1 3836 and we have shipped them 3271 bottles between 1 2 2 12/1/10 and 1/10/11." distribution center. There is 3271 bottles. The 3 Correct? 3 distribution center is asking you what do we do. 4 MR. SWANSON: Object to form, mischaracterizes 4 And what do you tell her on the first page, 5 the document. 5 Ms. Martin? б BY MR. MOUGEY: 6 Make sure I get this right. This is 7 Q. "I ran a query to see how many bottles 7 from you to her, right? 8 You don't make the call. You tell her 8 we have sent to store 3836 and we have shipped them 9 approximately 3271 bottles between 12/1/10 and 9 after 3200 bottles of a Schedule II to one 1/10/11." 10 10 pharmacy, you tell her, "Terry Collins is the 11 Did I read that right? 11 district pharmacy supervisor. His cell is," and 12 MR. SWANSON: Same objection. 12 you give her the cell, "He may be able to shed the 13 MR. MOUGEY: What's your objection, Counselor? 13 light on the subject." 14 MR. SWANSON: You said she wrote it. 14 Did I get that right? 15 MR. MOUGEY: You're right. These e-mails are 15 A. That's what I wrote, yes. 16 so jacked up. 16 Q. Yes, ma'am. Now, when you were 17 MR. SWANSON: Wasn't hard for me to figure 17 testifying to this jury about the due diligence you 18 18 would perform on orders that would -- that were out. 19 MR. MOUGEY: Yes, because you are so much 19 flagged, is this the kind of due diligence you 20 smarter than me. I appreciate that. You all 20 performed where you told the distribution center 21 remind me of that every day. I will work hard to after they ask you how do we check about the 21 get there. 22 22 viability, you tell them to contact the district 23 23 BY MR. MOUGEY: pharmacy supervisor? 24 24 Q. So here you are. I apologize. Let's That is one way of doing it. I can look

Page 338 Page 340 1 at sales history and I can see what was ordered. 1 Suspension to Walgreens Jupiter," and it cites to 2 2 But I'm not near that store. I don't have access Exhibit B. 3 3 to the prescriptions that they're filling and I Do you see that? 4 don't have access to any of their patient 4 A. I see that, yes. 5 5 information. Q. Okay. Let's go to Exhibit B. Go to the tab. It says Appendix B. It's dated September 13, 6 That is why I referred her to Terry who 6 7 7 is in the district, and he could go and work with 2012. 8 that store to determine why they're filling so many 8 Do you see that? 9 prescriptions for their patients. 9 A. I see that, yes. 10 10 Q. So, this is the typical type of due Q. That was one day after your e-mail to 11 diligence when you mentioned it earlier, you would 11 your boss informing him that the DEA had changed the locks on Walgreens' cage, correct? 12 tell the Jupiter distribution center that was 12 13 ultimately locked by the DEA that she should call 13 A. I don't remember the exact dates. 14 14 the district pharmacy supervisor, correct? This document, Exhibit B, Order to Show 15 MR. SWANSON: Object to form. 15 Cause and Immediate Suspension of Registration on 16 BY THE WITNESS: 16 Page No. 28 of 349, correct? 17 A. It's one of the types. Since I didn't 17 Do you see the page numbers in the 18 have access to this store's information, that's --18 middle of the page, 28 of 349? 19 I couldn't take any direct action. 19 A. At the bottom, yes. 20 (WHEREUPON, a certain document was 20 Yes, ma'am. And you see the title where 21 marked Walgreens-Martin Exhibit 21 it says Order to Show Cause and Immediate 22 22 Suspension of Registration, correct? No. 31: Binder of documents, 23 "Settlement and Memorandum of 23 A. Yes. 24 Agreement" and various other 24 And if you look at paragraph 1, it's Page 339 Page 341 1 documents; beginning Bates No. 1 referencing Walgreens Jupiter Florida distribution 2 2 WAGMDL00490963.) center, correct? Paragraph 1. 3 BY MR. MOUGEY: 3 A. Yes. 4 Q. I hand you what we're going to mark as 4 Q. If you look at paragraph 2, the first Martin 31, and I ask you to remember that store 5 5 sentence, "Since at least 2009, the State of б number. 6 Florida has been the epicenter of a notorious, 7 So, before we go to Exhibit 31, the 7 well-documented epidemic of prescription drug 8 abuse." 8 store number that she was asking about with the 9 3,200 bottles on Bates No. 47 is 3836. Okay? 9 Did I get that right? 10 Do you see that, 3836? 10 A. That's the statement written here, yes. 11 A. I see that, yes. 11 Q. And follows it up with, "In July of 12 Q. Martin 21 -- 31 is titled Settlement and 12 2011, the Florida Surgeon General declared a public 13 Memorandum of Agreement, correct? 13 health emergency based on the prescription pill 14 14 epidemic which results in an average of seven A. That's the title of this document, yes. 15 overdose deaths per day in Florida." Q. Yes, ma'am. And if you look at No. 4 on 15 16 Bates No. 63, you'll see that it references 16 Correct? 17 "Walgreens' Jupiter Distribution Center is 17 A. That's what this document says. 18 registered with the DEA as a distributor of 18 Q. The dates in paragraph 2 from 2009 to 19 Schedule II through IV." (As read.) 19 2011 cover the exact same time span when you and 20 Do you see that? Paragraph 4? 20 your colleagues at Walgreens are working on the 21 21 suspicious order monitoring policy with Mr. -- with A. Yes, I see that. 22 Q. You will see in paragraph 5, "On 22 Mr. Bancroft, correct? 23 September 13, 2012, the DEA by its Administrator 23 Yeah, that sounds right. 24 24 issued an Order to Show Cause and Immediate If you turn the page to page 30 of 349,

Page 342

Highly Confidential - Subject to Further Confidentiality Review

11

20

6

7

10

1 at the top of the page lists six store locations.

2 Do you see those?

3 A. Yes, I see those.

Q. And if you look at No. 4, 3836 is the 4

5 exact same store that Ms. At well was e-mailing you

б about in the beginning of 2011, correct?

A. That is, yes, one of the stores.

When she relays, "I ran a query to see

9 how many bottles we have sent to store 3836. We've

shipped them 3271 bottles from 12/1/10 to 1/10/11. 10

11 I don't know how they can keep this many bottles to

12 be" -- "how they can even house this many bottles

13 to be honest. How do we go about checking the

14 validity of these orders?"

15 Correct?

7

8

16 A. That's what she wrote, yes.

17 Q. Yes, ma'am. And if you look at No. 4 on

18 store 3836, oxycodone is Schedule II and one of the

19 most highly abused controlled substance --

20 controlled substances, correct?

21 A. By definition, when the DEA classifies a

22 product as a Schedule II, it's both highly

23 addictive and abusable.

24 And according to these numbers and the

agreement with the DEA, Walgreens went from 344,000 1

2 dosage units to 849,000 dosage units, correct?

3 MR. SWANSON: Object to form, mischaracterizes

4 the document you're reading from.

5 BY THE WITNESS:

6 A. I see the changes in numbers. Again,

7 I'm just not -- I'm not sure where this data is

8 coming from.

9 BY MR. MOUGEY:

10 Q. I understand. But let's just look --

let's do this just to clear up any confusion.

12 Turn to page 2 of 349 and keep your

13 thumb in 30 of 49. Do you see "Stipulation and

14 Agreement"?

15 A. I see that title.

16 Q. What do you understand, Ms. Martin, that

17 "Stipulation and Agreement" means?

18 A. I'm not really sure. This looks like a

19 very complicated legal document, and I would leave

it for someone that's more --

21 Q. Yes, ma'am, like Mr. Piñon to tell us.

22 Paragraph No. 2, "Walgreens acknowledges

23 that suspicious order reporting for distribution to

24 certain pharmacies did not meet the standards

Page 343

Page 344

1 agreement between Walgreens and the DEA in 2009,

2 there were 344,000 dosage units of oxycodone in

3 2009, correct?

4 MR. SWANSON: Object to form, characterization.

5 BY THE WITNESS:

б A. I'm not sure where this data is being

7 supplied from.

8 BY MR. MOUGEY:

9 Q. Yes, ma'am. Because you certainly

10 didn't go and look. You told her to contact the

11 pharmacy supervisor, correct?

12 MR. SWANSON: Object to form, argumentative.

13 BY MR. MOUGEY:

16

14 Q. Because you don't know the numbers,

15 correct? You never looked?

A. For this particular store, if you go

17 back on my e-mail, I was unable to look because I

18 was unable to access the store's system. Since I

19 didn't have any other information to justify the

20 information. I referred her to someone that was

21 closer to the store and could have helped her.

22 Q. While seven people a day in the State of

23 Florida are overdosing, the oxycodone purchases by

24 dosage unit from 2009 to 2010, according to the 1 identified by DEA in three letters from DEA Deputy

2 Assistant Director, Office of Diversion Control,

3 sent to every registered manufacturer and

4 distributor, including Walgreens, on September 27,

5 2006, February 7, 2007 and December 27, 2007."

Did I get that right?

MR. SWANSON: Object to the preface to that

8 question. Go ahead and answer.

9 BY MR. MOUGEY:

Q. Did I get that right, Ms. Martin?

11 I believe you read the words correctly.

12 Q. Do you recognize those dates as the

13 letters we went through earlier, September of '06,

14 February of '07 and December of '07?

15 A. Vaguely.

16 Q. Yes, ma'am. And you understand that

17 Walgreens is acknowledging that its suspicious

order reporting for the Jupiter distribution center 18

19 did not meet the standards identified in those

20 letters?

A. That's the verbiage on this form. 21

Yes, ma'am. That Walgreens signed and

agreed to, correct, ma'am? 23

I have no direct knowledge of who signed

22

24

Page 346

Highly Confidential - Subject to Further Confidentiality Review

2

1 it.

- 2 Q. I thought you might say that, so why
- 3 don't we turn to page 11 of 349, less than ten
- 4 pages after the Stipulation and Agreement wherein
- 5 "Walgreens acknowledges that suspicious order
- 6 reporting for distribution to certain pharmacies
- 7 did not meet the standards identified by the DEA,"
- 8 you see that Thomas Sabatino, executive vice
- 9 president, general counsel and corporate secretary,
- 10 signed on behalf of Walgreens on June 10, 2013,
- 11 correct?
- 12 A. I see that, yes.
- 13 Q. Yes, ma'am. So let's go back to page 30
- 14 of 349 and store 3836.
- 15 So, in the data provided in this
- 16 agreement, Walgreens dosage units of oxycodone from
- 17 the store that you were contacted about in
- 18 January of '11 went from 344,000 dosage units
- 19 according to this document to 849,000, correct?
- 20 MR. SWANSON: Object to the characterization.

increase of approximately 150% in the course of

Q. How about this. It's more than double?

Q. Now, you were contacted by Ms. Atwell

A. I don't -- I wouldn't be able to do

344,000 times 2 is 688,000, right, more than

those calculations in the top of my head.

- 21 BY THE WITNESS:
- 22 A. That's what the numbers on the form say.
- 23 BY MR. MOUGEY:

that one year, correct?

1 2

3

4

5

б

7

8

9

10

11

12

13

14

double?

24 And you understand that that is an

community is in store 3836, Port Richey, Florida? 1

Page 348

Page 349

- A. I -- I don't know that area.
- 3 Do you have Google on your computer?
- I do now. I don't know if I had it back 4
- 5 then.
- 6 Q. So, if you would have Googled Fort
- 7 Pierce back then, you would know -- I'm sorry --
- 8 Port Richey, you would have looked and found that
- 9 Port Richey, Florida has a population of
- 10 approximately 5,000 people.
- 11 5,000 people in January '11, over
- 12 1.4 million dosage units of oxycodone, correct?
- 13 MR. SWANSON: Object to form, assumes facts
- 14 not in evidence, foundation.
- 15 BY THE WITNESS:
- 16 A. I'm not sure I understand what you're
- 17 trying to ask me.
- 18 BY MR. MOUGEY:
- 19 Q. Yes, ma'am. If you would have looked in
- 20 January -- at the beginning of January '11, you
- 21 would have been able to determine that Port Richey,
- 22 Florida has a population of approximately 5,000
- 23 people and potentially prevented Walgreens from
- 24 dispensing 1.4 million dosage units in that

Page 347

1 community, correct?

> 2 MR. SWANSON: Object to form.

3 BY THE WITNESS:

- 4 A. Again, I'm still not sure what your
- 5 question is.
- б BY MR. MOUGEY:
- 7 Q. Yes, ma'am. As part of your due
- 8 diligence, did you even look to see how many people
- 9 lived in this community that you were contacted
- 10 about in January '11 about 3271 bottles coming off
- 11 the shelves?

13

- 12 A. I personally did not --
 - Q. Yes, ma'am.
- 14 A. -- look at the population. Quite
- 15 frankly, I would think that that would be -- do
- 16 more harm than good.

17 As a pharmacist, I wouldn't want to turn

- 18 away a patient just because they didn't live in the
- 19 same city my store was in. I personally live in
- 20 Chicago and I shop in a store in Park Ridge.
- 21 So, if I looked at just the population
- 22 of each city, and I said I can only fill that many
- 23 prescriptions, I think we would be doing more harm
- 24 than good to our patient population.

orders in the very beginning of 2011, January, correct? A. Got the dates on the e-mail. O. Yes, ma'am. A. Okay. Q. Very beginning of 2011, correct?

and asking you to check the validity of those

15 16

A. I'll agree to that, yes.

- 17 A. Yes, I see that.
- 18 Q. And in 2011, the dosage units to this
- 19 one store that you were contacted by -- about in
- 20 January, the annual dosage units for just oxycodone
- 21 were 1.4 million.
- 22 Do you see that?
- 23 A. I see that number, yes.
- 24 Do you have any idea how large the

Page 350 Page 352 And that's why I referred her to Terry BY MR. MOUGEY: 1 1 2 because he was in the area. He would know what 2 Q. I'm sorry? 3 3 that store is doing and if they had patients that A. I understand what the word means. I'd they were serving from other areas. like to know in what context you're trying to use 4 4 5 5 Q. So, the fact that when you looked, that 6 849,000 dosage units of oxycodone was given -- was 6 Q. Turn to page 38 of 349 of this same 7 7 being dispensed into a town of 5,000 people would document. Paragraph No. 23. The context that I'm 8 not have caused Barb Martin any alarm in the 8 referring to the use of the word "systemic" is 9 beginning of 2011? 9 "Voluntary dispensing restrictions enacted either 10 in anticipation of" -- are you there? MR. SWANSON: Object to form. 10 11 11 BY THE WITNESS: A. I'm sorry. I guess I'm -- because I 12 A. I wasn't looking at that data. 12 don't --13 BY MR. MOUGEY: 13 Q. Let's do the bottom --14 14 Q. Yes, ma'am, and that's not what I asked, You said page 48, right? if you looked at it. We've already established you 15 15 The bottom page numbers, 38 of 349. 16 didn't know that there was 5,000 people in that 16 A. I'm sorry. 17 community. What I asked was a little different. 17 38. That's okay. O. 18 If you had looked in the beginning of 18 I turned to 48. 19 2011 and you would have seen that 849,000 dosage 19 O. Paragraph 23. 20 units of oxycodone were being dispensed by 20 A. Okay. I see 23. "Voluntary dispensing restrictions 21 Walgreens where you had spent almost 25 years at 21 22 22 this point, would that have caused you any alarm? enacted either in anticipation of, or in reaction 23 MR. SWANSON: Object to form. 23 to regulatory action, do not indicate to me that 24 BY THE WITNESS: 24 the Respondent and its parent company have Page 351 Page 353 1 A. I would need to know more history than 1 recognized and adequately reformed the systemic 2 2 just a couple of the numbers on a piece of paper. shortcomings discussed herein." 3 BY MR. MOUGEY: 3 So, in that context, language from the 4 Q. And that's exactly the point of 4 DEA about Walgreens' systemic shortcomings, what performing due diligence, correct, Ms. Martin, is 5 5 does that mean to you, Ms. Martin? б that you gather information to make an educated б MR. SWANSON: Object on foundation. 7 decision, correct? 7 BY THE WITNESS: 8 8 A. And if I'm not capable of gathering that A. It's not my responsibility to determine 9 information, I find other people that can. 9 what the DEA means. I left that up to our legal 10 Q. So, when you told this jury earlier that 10 department. 11 you were performing due diligence on stores, your 11 BY MR. MOUGEY: 12 realm of expertise, your wheelhouse does not even 12 Q. Sitting here today in 2018, to this 13 include Googling the city where the pharmacy is 13 jury, when I'm asking you what the word "systemic 14 located to see what the population is? 14 shortcoming" means in this document from the DEA, 15 15 you don't have the wherewithal or the ability to Again, I don't see how that's relevant. 16 I wouldn't want to limit patients to only go to 16 tell me what that means? 17 pharmacies in the city they live in. 17 MR. SWANSON: Object to form. 18 Q. Do you understand what the word 18 BY THE WITNESS: 19 "systemic" means, Ms. Martin? 19 A. Again, I'm not comfortable making a 20 A. I guess it depends in what context you 20 legal decision on a legal document. 21 want to use the word. 21 BY MR. MOUGEY: 22 Q. Just systemic. Corporate-wide. Do you 22 Q. I'm asking you to tell us what the 23 understand what "systemic" means? 23 meaning of a word, "systemic," is in a sentence. 24 MR. SWANSON: Object to form. 24 You're not comfortable making that

Page 354 Page 356 look into it and respond if required. 1 determination today? 1 2 MR. SWANSON: Objection; foundation. 2 MR. MOUGEY: That's fine. Thank you. 3 3 BY THE WITNESS: MR. SWANSON: Thanks. A. I'm not comfortable responding on a 4 4 **EXAMINATION** 5 5 BY MR. SWANSON: legal document. 6 BY MR. MOUGEY: 6 Q. So, Ms. Martin, it's been a long day, 7 7 Q. Yet you're telling this jury that from and I know you're tired; and I promise that I'm not 8 the middle of 2008 until the end of 2012, you were 8 going to take a whole lot more of your time, but I 9 a material participant in developing Walgreens' 9 do have just a few questions that I hope I can ask suspicious order monitoring policies and 10 and you can help clarify some questions that I had 10 11 procedures, correct? 11 from your earlier testimony. 12 A. I was one of a number of people involved 12 Earlier, actually for a good part of the 13 with the processes, yes. 13 afternoon today, Mr. Mougey went through several 14 14 Q. You were one of a number of people who documents with you, memoranda, business requirement 15 were charged with the objective of identifying and 15 documents, et cetera, that related to the 16 reporting suspicious orders to the DEA, correct? 16 suspicious order monitoring system that you had 17 17 A. I thought our objective was more coming some involvement in working on. 18 up with system enhancements. I wasn't involved 18 Do you recall that generally? 19 A. Yes. with the reporting part. 19 20 MR. MOUGEY: Let me take a quick break and let 20 Q. And he focused a lot of his attention on 21 me review what I got left. How much time do we 21 a specific word that was contained in those 22 22 reports, and that was "suspicious orders." Do you have left? 23 THE VIDEOGRAPHER: Got about 27 minutes. 23 remember that? 24 MR. MOUGEY: Thank you. 24 Yes. A. Page 357 1 THE VIDEOGRAPHER: We're going off the record 1 Q. And there were some back-and-forth 2 2 between you and Mr. Mougey over whether that was a at 5:33. 3 (WHEREUPON, a recess was had 3 reference to an actual suspicious order or a 4 from 5:33 to 5:53 p.m.) 4 potential or possible suspicious order. Do you 5 THE VIDEOGRAPHER: We're back on the record at 5 recall that? 6 5:53. 6 A. Yes. 7 MR. MOUGEY: I don't have any further 7 Q. And can you tell us what your understanding of that term "suspicious order" as it 8 8 questions other than the issue of the performance 9 review. I just wanted a confirmation that if we 9 was used in those business requirement documents 10 are not getting performance reviews in specific 10 referred to? 11 A. Even though the document didn't use the years, does that mean that they don't exist or that 11 12 there is no reference to opiate-related performance 12 word "potentially," that was what my belief was, 13 in that review. 13 that we were looking for orders that had the 14 So, subject to that answer, because I 14 potential to be suspicious. But until we did more 15 believe we're supposed to be receiving them prior, 15 evaluations of those orders, we weren't sure 16 72 hours prior to the depos, that's the only 16 whether they were suspicious or not. 17 caveat. I don't have any questions and don't 17 Q. And he pulled out or he showed you 18 anticipate a problem, but I would just appreciate 18 during the course of the day a couple of different 19 an answer. 19 reports, and I'd like to ask you about those now. 20 MR. SWANSON: Okay. So I don't have an answer 20 The first is, was marked Martin 21 right now, as I told you. You understand. My 21 Exhibit No. 2. Could you pull that out, please. 22 understanding is we have tried to answer that 22 A. Here I have it. 23 23 Q. Okay. And is Martin Exhibit No. 2 one question for you. If it hasn't been done to your 24 satisfaction, I can't speak to that but we will 24 of the reports that was generated by the system

Page 358

Highly Confidential - Subject to Further Confidentiality Review

1 that you were asked questions about today?

- 2 A. Yes.
- 3 Q. And if you look, it's a document dated
- August 25 of 2009, right? 4
- 5 A. Correct.
- 6 Q. And in the top right corner, it says
- 7 "Suspicious Order," right?
- 8 A. Right. That's the name that we were
- 9 using.
- 10 Q. Okay. And as you review Martin
- 11 Exhibit 2, is this a document that you -- well, let
- 12 me ask you first a prefatory question.
- 13 Was this a document, Martin 2, a
- 14 document that was flagged by the system for you to
- 15 review?
- 16 A. This item was flagged, yes.
- 17 Q. If you look at Martin Exhibit 2, do you
- 18 consider this to be a suspicious order as you
- 19 understand that term?

tolerance limit of 5.

to be a suspicious order?

- 20 A. I do not consider this to be a
- 21 suspicious order. My reasoning for that is that
- 22 the suggested order quantity and the ordered
- 23 quantity are both 3. So, there was no changes that

order. And then that number 3 is well below the

Q. So, even though Martin Exhibit 2 was a

"Suspicious Order" on it, you don't consider this

report that was flagged by the system, it said

24 the store made from what our system wanted to 1 a suspicious order?

- 2 A. I do not consider this order to be
- 3 suspicious either. While the suggested quantity,

Page 360

Page 361

- 4 the system order was zero, there was an order by a
- 5 store user with a user ID of Zulic that ordered a
- 6 quantity of 2. This is equal to the tolerance
- 7 limit, so I would not consider this suspicious.

8 They could have been punching this order

- 9 manually for a number of different reasons. The
- 10 first one that would come to my mind would be the
- 11 fact that it's possible without seeing any other
- 12 different information that this store never had an
- 13 order history in the past. If they hadn't had it
- 14 before and a new patient presented a prescription,
- 15 the system wouldn't know to order it. They would
- 16 have to order it manually.
- 17 Q. So, even though Martin Exhibit 20 was a
- 18 report that was flagged by the system marked as a
- 19 suspicious order, you don't consider this to be in
- 20 fact a suspicious order?
- 21 A. I do not think this is a suspicious
- 22 order.
- 23 Q. Was it flagged as a potential suspicious
- 24 order?

2

7

Page 359

1 A. It was flagged for our review, which is

- why I kept using the term "potentially suspicious."
- 3 MR. SWANSON: Thank you. That clarified it
- 4 for me. I don't have any more questions.
- 6 questions, Ms. Martin.

7 A. No.

1

2

3

4

5

б

- 8 Q. And then the only other document he
- 9 showed you a report that he showed you was Martin
- 10 Exhibit 20. Can you pull that one out, please.
- 11 A. Might be faster if I just look on the
- 12 screen.
- 13 Q. Okay. That's fine. Thank you.
- 14 This is another report that Mr. Mougey
- 15 showed you, again, with a title or a -- the words
- 16 on there "Suspicious Order."
- 17 Do you see that in the upper right
- 18 corner?
- 19 A. Yes.
- 20 Q. And was this a report that was flagged
- 21 by the system that Mr. Mougey asked you about
- 22 today?
- 23 A. Yes.
- 24 Do you consider Martin Exhibit 20 to be

- 5 MR. MOUGEY: I have a couple follow-up
- - **FURTHER EXAMINATION**
- 8 BY MR. MOUGEY:
- 9 Q. So, how many years did you review these
- reports? 10
- 11 Somewhere between 2 and 4.
- 12 O. Somewhere between 2 and 4. So,
- 13 beginning of 2009 to late 2012, right?
- 14 A. Middle 2012 when the Rx Integrity team
- 15 came and there were various iterations of this form
- 16 as well.
- 17 Q. Now, what was produced out of your file
- was about 22 or 23 of these suspicious order 18
- 19 reports. Do you have any idea why you had 22 or 23
- 20 of these reports isolated?
- 21 A. I have no idea why I chose to kept
- 22 those.
- 23 Q. You just happened to keep 22 or 23 of
- 24 these reports?

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 93 of 117. PageID #: 167559 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 94 of 117. PageID #: 167560 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP	Doc #: 1965-52	Filed:	07/23/19	95 of 117.	PageID #: 167561
REDACTED					

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 96 of 117. PageID #: 167562 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 97 of 117. PageID #: 167563
Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 98 of 117. PageID #: 167564 Highly Confidential - Subject to Further Confidentiality Review Page 375 REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 99 of 117. PageID #: 167565 Highly Confidential - Subject to Further Confidentiality Review

Page 376

REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 100 of 117. PageID #: 167566 Highly Confidential - Subject to Further Confidentiality Review

	Page 377	
REDACTED		

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 101 of 117. PageID #: 167567 Highly Confidential - Subject to Further Confidentiality Review Page 378 REDACTED

	Highly	Confidential	- Subject	to Further	Confidentiality 1	Review		
							Page 3'	79
REDACTE	D							

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 103 of 117. PageID #: 167569 Highly Confidential - Subject to Further Confidentiality Review

Page 380

REDACTED		

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 104 of 117. PageID #: 167570 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 105 of 117. PageID #: 167571 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 106 of 117. PageID #: 167572 Highly Confidential - Subject to Further Confidentiality Review Page 383 REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 107 of 117. PageID #: 167573 Highly Confidential - Subject to Further Confidentiality Review Page 384 REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 108 of 117. PageID #: 167574 Highly Confidential - Subject to Further Confidentiality Review

Ρ		3	

REDACTED	

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 109 of 117. PageID #: 167575 Highly Confidential - Subject to Further Confidentiality Review

Page 386

REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 110 of 117. PageID #: 167576 Highly Confidential - Subject to Further Confidentiality Review

	Page	387
REDACTED		
REDACTED		

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 111 of 117. PageID #: 167577 Highly Confidential - Subject to Further Confidentiality Review

Page 388

REDACTED		

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 112 of 117. PageID #: 167578 Highly Confidential - Subject to Further Confidentiality Review

Page 389

REDACTED		

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 113 of 117. PageID #: 167579 Highly Confidential - Subject to Further Confidentiality Review

	Page	390
REDACTED		

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 114 of 117. PageID #: 167580 Highly Confidential - Subject to Further Confidentiality Review Page 391 REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 115 of 117. PageID #: 167581 Highly Confidential - Subject to Further Confidentiality Review REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 116 of 117. PageID #: 167582 Highly Confidential - Subject to Further Confidentiality Review Page 393 REDACTED

Case: 1:17-md-02804-DAP Doc #: 1965-52 Filed: 07/23/19 117 of 117. PageID #: 167583 Highly Confidential - Subject to Further Confidentiality Review

Page 394

REDACTED